FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082967508> ?p ?o ?g. }

• W3082967508 endingPage "A12" @default.
• W3082967508 startingPage "A12" @default.
• W3082967508 abstract "Abstract Epidemiologic studies and meta-analyses have indicated that metformin is associated with a lower incidence of tumorigenesis among type 2 diabetic patients, including those with head and neck squamous cell carcinoma (HNSCC). HNSCC patients are often treated with concurrent cisplatin-based chemotherapy and radiation (CRT). However, the cure rate remains low at 50% in HPV-negative smokers. Metformin has been shown to inhibit tumor growth and progression, both in vitro and in mouse models, in a wide variety of cancers including HNSCC. The mechanism through which this occurs is thought to be via the inhibition of the mammalian target of rapamycin (mTOR) pathway directly and indirectly through activation of AMPK. Recent studies indicate that increasing the activity of AMPK reduces the expression of PD-L1 found on the surface of cancer cells, thus allowing a greater influx of CD8+ T cells and further activity of NKT cells correlated with increased tumor cell killing. Given the potential antitumorigenic activity of metformin in HNSCC and that biguanide is generally well tolerated compared to other mTOR inhibitors, we hypothesized that the addition of metformin to CRT would be safe and would result in enhanced antitumor responses through activation of AMPK and the immune system. Therefore, in accordance with the phase I open-label, single-site, dose-escalation study combining metformin and CRT in LAHNSCC (NCT02325401), we investigated the effects of metformin on T cells, NK cells, and cytokines from patient PBMCs. Using flow cytometry and cytokine magnetic bead assays (Luminex), we evaluated the immune cell phenotypes and cytokine profiles of peripheral blood in patients before and after metformin treatment on trial. Cytokine profiles were further studied in coculture experiments combining PBMCs, HNSCC cell lines, and metformin. Following metformin treatment, patients developed an increase in activated NK cell populations, determined via NKG2D expression, as well as a shift in their CD8+ T-cell memory phenotypes. Patient serum ELISA examination revealed alterations in cytokine profiles, which were recapitulated in ex vivo experiments. Metformin treatment of HNSCC cell lines in vitro as well as HNSCC PBMCs ex vivo resulted in downregulation of STAT3 compared to healthy controls. Downregulation of STAT3 may be a potential mechanism in which metformin activates NK cells. Here we show evidence that metformin treatment has a direct effect on the innate immune system in patients with LAHNSCC, inducing an antitumorigenic immune response. Our study thus demonstrates that metformin continues to be a good candidate in combination with other therapeutic agents to yield improved clinical outcomes in patients with advanced-stage HNSCC. Citation Format: Sarah M. Palackdharry, Benyamin Yaniv, Melissa Orr-Asman, Nooshin Hashemi, Vinita Takiar, Trisha Wise-Draper. Metformin treatment in LAHNSCC induces an antitumorigenic immune response [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; 2019 Apr 29-30; Austin, TX. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_2):Abstract nr A12." @default.
• W3082967508 created "2020-09-08" @default.
• W3082967508 creator A5004510657 @default.
• W3082967508 creator A5011589152 @default.
• W3082967508 creator A5044665651 @default.
• W3082967508 creator A5061224094 @default.
• W3082967508 creator A5064686412 @default.
• W3082967508 creator A5086177096 @default.
• W3082967508 date "2020-06-15" @default.
• W3082967508 modified "2023-10-05" @default.
• W3082967508 title "Abstract A12: Metformin treatment in LAHNSCC induces an antitumorigenic immune response" @default.
• W3082967508 doi "https://doi.org/10.1158/1557-3265.aacrahns19-a12" @default.
• W3082967508 hasPublicationYear "2020" @default.
• W3082967508 type Work @default.
• W3082967508 sameAs 3082967508 @default.
• W3082967508 citedByCount "0" @default.
• W3082967508 crossrefType "journal-article" @default.
• W3082967508 hasAuthorship W3082967508A5004510657 @default.
• W3082967508 hasAuthorship W3082967508A5011589152 @default.
• W3082967508 hasAuthorship W3082967508A5044665651 @default.
• W3082967508 hasAuthorship W3082967508A5061224094 @default.
• W3082967508 hasAuthorship W3082967508A5064686412 @default.
• W3082967508 hasAuthorship W3082967508A5086177096 @default.
• W3082967508 hasConcept C121608353 @default.
• W3082967508 hasConcept C126322002 @default.
• W3082967508 hasConcept C134018914 @default.
• W3082967508 hasConcept C167672396 @default.
• W3082967508 hasConcept C184235292 @default.
• W3082967508 hasConcept C190283241 @default.
• W3082967508 hasConcept C203014093 @default.
• W3082967508 hasConcept C2776530083 @default.
• W3082967508 hasConcept C2776833033 @default.
• W3082967508 hasConcept C2777688063 @default.
• W3082967508 hasConcept C2778690821 @default.
• W3082967508 hasConcept C2780124434 @default.
• W3082967508 hasConcept C2780323712 @default.
• W3082967508 hasConcept C502942594 @default.
• W3082967508 hasConcept C55493867 @default.
• W3082967508 hasConcept C555293320 @default.
• W3082967508 hasConcept C71924100 @default.
• W3082967508 hasConcept C86554907 @default.
• W3082967508 hasConcept C86803240 @default.
• W3082967508 hasConcept C8891405 @default.
• W3082967508 hasConcept C95444343 @default.
• W3082967508 hasConcept C97029542 @default.
• W3082967508 hasConceptScore W3082967508C121608353 @default.
• W3082967508 hasConceptScore W3082967508C126322002 @default.
• W3082967508 hasConceptScore W3082967508C134018914 @default.
• W3082967508 hasConceptScore W3082967508C167672396 @default.
• W3082967508 hasConceptScore W3082967508C184235292 @default.
• W3082967508 hasConceptScore W3082967508C190283241 @default.
• W3082967508 hasConceptScore W3082967508C203014093 @default.
• W3082967508 hasConceptScore W3082967508C2776530083 @default.
• W3082967508 hasConceptScore W3082967508C2776833033 @default.
• W3082967508 hasConceptScore W3082967508C2777688063 @default.
• W3082967508 hasConceptScore W3082967508C2778690821 @default.
• W3082967508 hasConceptScore W3082967508C2780124434 @default.
• W3082967508 hasConceptScore W3082967508C2780323712 @default.
• W3082967508 hasConceptScore W3082967508C502942594 @default.
• W3082967508 hasConceptScore W3082967508C55493867 @default.
• W3082967508 hasConceptScore W3082967508C555293320 @default.
• W3082967508 hasConceptScore W3082967508C71924100 @default.
• W3082967508 hasConceptScore W3082967508C86554907 @default.
• W3082967508 hasConceptScore W3082967508C86803240 @default.
• W3082967508 hasConceptScore W3082967508C8891405 @default.
• W3082967508 hasConceptScore W3082967508C95444343 @default.
• W3082967508 hasConceptScore W3082967508C97029542 @default.
• W3082967508 hasIssue "12_Supplement_2" @default.
• W3082967508 hasLocation W30829675081 @default.
• W3082967508 hasOpenAccess W3082967508 @default.
• W3082967508 hasPrimaryLocation W30829675081 @default.
• W3082967508 hasRelatedWork W185214937 @default.
• W3082967508 hasRelatedWork W1948575454 @default.
• W3082967508 hasRelatedWork W2000633272 @default.
• W3082967508 hasRelatedWork W2163857416 @default.
• W3082967508 hasRelatedWork W2791348101 @default.
• W3082967508 hasRelatedWork W2888022043 @default.
• W3082967508 hasRelatedWork W2913571569 @default.
• W3082967508 hasRelatedWork W2923024569 @default.
• W3082967508 hasRelatedWork W3206779302 @default.
• W3082967508 hasRelatedWork W4200067813 @default.
• W3082967508 hasVolume "26" @default.
• W3082967508 isParatext "false" @default.
• W3082967508 isRetracted "false" @default.
• W3082967508 magId "3082967508" @default.
• W3082967508 workType "article" @default.